Intracoronary hyperoxemic oxygen therapy delivered to the LMCA after PCI in anterior STEMI was safe, with a 30-day NACE rate of 7.1% compared to an objective performance goal of 10.7%.
Cohort (n=100)
Is intracoronary hyperoxemic oxygen therapy delivered to the LMCA after PCI safe and feasible in patients with anterior STEMI?
Intracoronary hyperoxemic oxygen therapy delivered to the LMCA for 60 minutes after PCI in anterior STEMI is feasible and has a favorable 30-day safety profile.
Absolute Event Rate: 7.1% vs 10.7%
BACKGROUND: ] delivered into the left anterior descending (LAD) artery via an indwelling intracoronary infusion catheter following primary percutaneous coronary intervention (PCI) significantly reduced infarct size in patients with anterior ST-segment elevation myocardial infarction (STEMI) but resulted in a numerically higher incidence of safety events. OBJECTIVES: therapy selectively delivered to the left main coronary artery (LMCA) for 60 minutes after PCI in patients with anterior STEMI. METHODS: therapy was administered to the LMCA after stent implantation in 100 patients with anterior STEMI and proximal or mid-LAD occlusion presenting within 6 hours of symptom onset. The primary endpoint was the 30-day composite rate of net adverse clinical events (NACE) (death, reinfarction, clinically driven target vessel revascularization, stent thrombosis, severe heart failure, or TIMI major/minor bleeding) compared against an objective performance goal of 10.7%. Cardiac magnetic resonance imaging was performed at 4 and 30 days to assess infarct size. RESULTS: delivery was successful in 98% of patients. NACE at 30 days occurred 7.1% of patients (meeting the primary safety endpoint of the study); there were no deaths, only one stent thrombosis and one case of severe heart failure. Median interquartile range infarct size was 24.1% 14.4%, 31.6% at 4 days and 19.4% 8.8%, 28.9% at 30 days. CONCLUSION: via the LMCA was feasible and was associated with a favorable early safety profile.
David et al. (Fri,) conducted a cohort in anterior ST-segment elevation myocardial infarction (STEMI) (n=100). Intracoronary hyperoxemic oxygen therapy vs. Objective performance goal was evaluated on 30-day composite rate of net adverse clinical events (NACE) (death, reinfarction, clinically driven target vessel revascularization, stent thrombosis, severe heart failure, or TIMI major/minor bleeding). Intracoronary hyperoxemic oxygen therapy delivered to the LMCA after PCI in anterior STEMI was safe, with a 30-day NACE rate of 7.1% compared to an objective performance goal of 10.7%.